Status:
COMPLETED
Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT)
Lead Sponsor:
University College, London
Collaborating Sponsors:
Medical Research Council
Conditions:
Haematological Malignancies
Eligibility:
All Genders
16+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to evaluate whether the administration of allodepleted donor T cells to patients with haematological malignancies after stem cell transplant can improve the recovery of th...
Eligibility Criteria
Inclusion
- Age ≥16 years
- Underlying haematological malignancy
- Planned allogeneic peripheral blood stem cell transplantation from a 10/10 or 9/10 HLA matched unrelated donor, using an Alemtuzumab-based conditioning protocol
- Written Informed consent
Exclusion
- Life expectancy \< 6 weeks
- Female patients who are pregnant and lactating
- Patients who are serologically positive for Hepatitis B, C or HIV pre-SCT
Key Trial Info
Start Date :
July 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2020
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT01827579
Start Date
July 1 2014
End Date
January 1 2020
Last Update
July 21 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University College London Hospital
London, United Kingdom
2
Manchester Royal Infirmary
Manchester, United Kingdom